Secondary atypical hemolytic uremic syndromes in the era of complement blockade

Manuel Praga; Santiago Rodríguez de Córdoba

doi:10.1016/j.kint.2019.01.043

Secondary atypical hemolytic uremic syndromes in the era of complement blockade

Kidney Int. 2019 Jun;95(6):1298-1300. doi: 10.1016/j.kint.2019.01.043.

Authors

Manuel Praga¹, Santiago Rodríguez de Córdoba²

Affiliations

¹ Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12) and Department of Medicine, Complutense University, Madrid, Spain. Electronic address: [email protected].
² Department of Cellular and Molecular Medicine, Center for Biological Research and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain.

PMID: 31122707
DOI: 10.1016/j.kint.2019.01.043

Abstract

Le Clech et al. found rare variants in complement genes in only 5% of patients among a large cohort of secondary hemolytic uremic syndrome cases. The absence of genetic abnormalities does not exclude, however, the implication of complement in the pathogenesis of secondary hemolytic uremic syndrome. Prospective studies should be performed to evaluate the efficacy of complement blockers in patients with secondary atypical hemolytic uremic syndrome who do not respond to the treatment of the triggering condition.

Publication types

Comment

MeSH terms

Atypical Hemolytic Uremic Syndrome*
Complement System Proteins
Humans
Prospective Studies
Risk Factors

Substances

Complement System Proteins